Inhibitex, Inc. was upgraded by Deutsche Bank Thursday to a “buy” rating.
Inhibitex, Inc. closed Thursday at $3.96
Target Your Profits Higher!
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR BLOG POST.
Visit AimHighProfits.com to learn more ...
Continue Reading →Penny Stock To Watch: Inhibitex, Inc. (NASDAQ:INHX)
Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include FV-100, an orally available nucleoside analogue prodrug, which is in Phase II trials for the treatment of herpes zoster or shingles; and INX-189, a HCV nucleoside polymerase inhibitor that ...
Continue Reading →